Loading...
XNAS
BFRI
Market cap10mUSD
Oct 08, Last price  
0.92USD
1D
-1.77%
1Q
-16.47%
IPO
-98.96%
Name

Biofrontera Inc

Chart & performance

D1W1MN
XNAS:BFRI chart
P/E
—
P/S
0.24
EPS
—
Div yield, %
—
Shrs. gr., 5y
82.21%
Rev. gr., 5y
17.21%
Revenues
42m
+11.80%
26,181,00018,849,00024,100,00028,674,00034,071,00037,303,00041,705,000
Net income
-11m
L-40.67%
-10,982,000-10,987,000-37,713,000-640,000-20,131,000-17,759,000-10,536,000
CFO
-13m
L+30.10%
-37,677,000-12,369,000-26,715,000-16,199,000-24,895,000-10,270,000-13,361,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
URL
https://www.biofrontera-us.com/
IPO date
Oct 14, 2021
Employees
81
Domiciled in
US
Incorporated in
US
Legal address
850 NEW BURTON ROAD SUITE 201
DOVER, DE 19904
US
Headquarters
120 PRESIDENTIAL WAY, SUITE 330
WOBURN, MA 01801
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT